<DOC>
	<DOCNO>NCT02171741</DOCNO>
	<brief_summary>Study determine maximum tolerate dose ( MTD ) various treatment duration BIBW 2992 administer combination docetaxel determine drug-related adverse event ( AEs ) well Pharmacokinetics , overall safety antitumor efficacy .</brief_summary>
	<brief_title>Dose Escalation Trial BIBW 2992 Administration Combination With Docetaxel Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Male female patient confirm diagnosis advance , nonresectable / metastatic solid tumor , type historically know express EGFR and/or HER2 , amenable docetaxel , preferably patient breast , prostate , nonsmall cell lung cancer . Patients must fail prior standard therapy associate clinical benefit , include survival benefit , therapy available . If docetaxel administration standard therapy associate clinical benefit , patient eligible Age 18 year old Life expectancy least three ( 3 ) month Written inform consent consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Patients must resolution prior chemo , hormone , immuno , radiotherapy related toxicity CTC Grade &lt; = 1or baseline individual patient Patients must recover previous surgery Active infectious disease Gastrointestinal disorder may interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight week , history cerebral edema bleed past eight week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction ≥ CTC Grade 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin &gt; upper limit normal ( ULN ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) &gt; 1.5 x ULN Alkaline Phosphatase &gt; 2.5 x ULN Serum creatinine &gt; 1.5 mg / dl ( &gt; 132 μmol / L , SI ( Système Internationale ) unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Concurrent treatment investigational drug , chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude Luteinizing hormonereleasing hormone agonist , hormone take breast cancer , bisphosphonates ) participation another clinical study within past four week start therapy concomitantly study Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( 8 week trastuzumab ) Patients unable comply protocol Active alcohol drug abuse Hypersensitivity docetaxel component drug formulate polysorbate 80 The patient may eligible retreatment previous course finish . The patient eligible follow condition meet : If patient ' late Xray , CT MRI reveal progressive disease , clinical assessment reveals sign disease progression Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria list determined treatment Day 1 new course Patient recover doselimiting toxicity ( DLT ) 14 day onset . Recovery define return baseline level CTC Grade 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>